Researchers are working overtime to develop therapies that, for the first time, specifically target Guillain-Barré Syndrome.
Men’s Health spoke to say they spend more time at home now than they did before the pandemic. Now, in spring 2025, life ...
Business Eye on MSN3d
Two New Board Members Appointed To The Office Of Public WorksThe Office of Public Works (OPW) is pleased to announce two significant appointments to its Board of Management. Conor ...
What is Guillain-Barré syndrome? Guillain-Barré syndrome (GBS) is also called acute inflammatory demyelinating polyradiculoneuropathy (AIDP). It's a neurological disorder in which the body's immune ...
An ongoing open-label, single arm, POC study is evaluating ANX1502 in patients with cold agglutinin disease (CAD) for up to four weeks to evaluate tolerability, pharmacokinetics, pharmacodynamic and ...
A GB News commentator has claimed the Vatican and Pope Francis are trying to quell speculation about his condition with their constant updates. Comparing the situation to Princess Kate's cancer ...
GB News star Darren Grimes has announced he is leaving the show live on-air, leaving fans devastated. Ahead of his show, Darren warned via X: "I will be making an announcement on tonight's episode ...
Senators Thom Tillis (R-NC) and Mark Kelly (D-AZ) introduced the bipartisan Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act, legislation to ensure individuals with rare ...
CONSHOHOCKEN, Pa., Feb. 28, 2025 /PRNewswire/ -- The GBS | CIDP Foundation International today released new survey data illustrating how people with Guillain-Barré Syndrome experience this life ...
“We have seen patients where they don’t know what the trigger was, but most often you typically hear about the preceding infection of some kind,” said Donna Hartlem, the executive director of GBS/CIDP ...
The full GBS Patient Registry Report is available here.You can watch recordings of this year's State of the Science meetings here. For more information, please visit www.gbs-cidp.org or contact ...
He noted the significant early impact on CIDP and progress in clinical milestones, including advancing empasiprubart and efgartigimod into Phase III programs. Van Hauwermeiren announced that 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback